Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocotrienol with Neoadjuvant Chemotherapy for Breast Cancer
NCT02909751Phase 2Completed
- Sponsor
- Vejle Hospital
- Start
- Sep 2016
- Primary completion
- Jan 2019
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial (2 arms), sponsored by Vejle Hospital. Primary endpoint: Pathological complete response at 26 weeks. Started Sep 2016; status: completed.
Beyond the preview
Go deeper on NCT02909751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02909751.